GH vs. FTRE, RDNT, VCYT, VRDN, CDNA, FLGT, BNR, PSNL, EXAS, and IOVA
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Fortrea (FTRE), RadNet (RDNT), Veracyte (VCYT), Viridian Therapeutics (VRDN), CareDx (CDNA), Fulgent Genetics (FLGT), Burning Rock Biotech (BNR), Personalis (PSNL), Exact Sciences (EXAS), and Iovance Biotherapeutics (IOVA).
Guardant Health (NASDAQ:GH) and Fortrea (NASDAQ:FTRE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
In the previous week, Fortrea had 25 more articles in the media than Guardant Health. MarketBeat recorded 35 mentions for Fortrea and 10 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.62 beat Fortrea's score of 0.37 indicating that Guardant Health is being referred to more favorably in the media.
Guardant Health presently has a consensus price target of $35.78, suggesting a potential upside of 41.08%. Fortrea has a consensus price target of $35.57, suggesting a potential upside of 29.12%. Given Guardant Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Guardant Health is more favorable than Fortrea.
92.6% of Guardant Health shares are held by institutional investors. 6.2% of Guardant Health shares are held by insiders. Comparatively, 0.1% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Guardant Health received 256 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 68.75% of users gave Guardant Health an outperform vote while only 47.06% of users gave Fortrea an outperform vote.
Fortrea has higher revenue and earnings than Guardant Health. Fortrea is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.
Fortrea has a net margin of -4.11% compared to Guardant Health's net margin of -76.34%. Fortrea's return on equity of 4.76% beat Guardant Health's return on equity.
Summary
Guardant Health beats Fortrea on 10 of the 18 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
